Log in to search using one of your social media accounts:

 

2018 Annual Review of the Blueprint List of Priority Diseases
World Health Organization. 02/08/2018 This Web page provides the 2018 List of Priority Diseases, which include Ebola virus disease and Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS), and Zika virus. Experts consider that given their potential to cause a public health emergency and the absence of efficacious drugs and/or vaccines, there is an urgent need for accelerated research and development for these diseases. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - February 10, 2018 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

Ebola virus infects reproductive organs in monkeys
Additional research is needed to determine if drugs and vaccines can cure or prevent such infections, and to understand the mechanisms of sexual transmission. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 8, 2018 Category: American Health Source Type: news

Antibodies Against Ebola and Lassa: A Global Collaboration
National Institute of Allergy and Infectious Diseases [National Institutes of Health]. 12/05/2017 This 53-minute presentation, the 2017 Kinyoun Lecture, explores the features of antibodies that protect against the deadly Ebola and Lassa viruses, and the ongoing need for scientists to collaborate in this research to establish a complete knowledge base. During the past three years, Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC) researchers from dozens of labs on five continents have studied these protective antibodies. The VIC aims to fill critical knowledge gaps and provide a foundation of research that can be u...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - January 5, 2018 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

UK vaccine research hub to bolster fight against lethal viruses
Imperial College centre aims to help poorer countries respond to epidemics like Ebola (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 27, 2017 Category: Pharmaceuticals Source Type: news

Antibodies Against Ebola and Lassa: A Global Collaboration
National Institutes of Health. 12/05/2017 This 53-minute lecture explores the features of antibodies that protect against the deadly Ebola and Lassa viruses and the ongoing need for scientists to collaborate in this research to establish a complete knowledge base. During the past three years, Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC) researchers from dozens of labs on five continents have studied these protective antibodies. The VIC aims to fill critical knowledge gaps and provide a foundation of research that can be used to improve existing vaccines and antivirals, and to evaluate the pipeline of candidat...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - December 20, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

2017 Research Highlights — Clinical Advances
NIH accomplishments in the prevention, diagnosis, and treatment of human disease. These include progress on two Ebola vaccines, a bionic pancreas to treat type 1 diabetes, and a genetic test that improves blood thinner dosing. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - December 15, 2017 Category: Consumer Health News Source Type: news

40 years after first Ebola outbreak, survivors show signs they can stave off new infection
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study led by researchers at the UCLA Fielding School of Public Health.UCLA researchers located the 14 Ebola survivors of the 1976 outbreak who, in January 2016, were still living in the same small, remote villages in the forests of the Équateur Province of northwestern Democratic Republic of the Congo. The researchers obtained blood samples and health history reports from them. The data revealed evidence ...
Source: UCLA Newsroom: Health Sciences - December 14, 2017 Category: Universities & Medical Training Source Type: news

Forty years after first Ebola outbreak, survivors show signs they can stave off new infection
(University of California - Los Angeles Health Sciences) Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks. UCLA researchers located the 14 Ebola survivors of the 1976 outbreak who, in January 2016, were still living in the same small, remote villages in the forests of the É quateur Province of northwestern Democratic Republic of the Congo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 14, 2017 Category: Infectious Diseases Source Type: news

Altmetric announces the top 100 list for 2017
This study revealed a Dinosaur species had teeth that it lost as it aged. Testing of an Ebola vaccine during the West African outbreak found that it was completely effective – offering hope should the virus return. The development of an artificial womb for lambs has opened new possibilities for their application amongst humans. Topical issues Some key themes stood out. Scientific research, technology, humanity and environmental science continue to intersect and capture the public’s attention. The most widely discussed research topics in 2017 were: Medical Science (53) Biological Science (17) Earth and Environ...
Source: News from STM - December 12, 2017 Category: Databases & Libraries Authors: STM Publishing News Tags: Digital Featured Source Type: news

GM humans: New vaccines made with synthetic genes will alter your DNA
(Natural News) Back in 2015, The New York Times published an article entitled, “Protection Without a Vaccine,” an in-depth look at immunoprophylaxis by gene transfer, or I.G.T. Described as a “novel approach” to fighting serious diseases like H.I.V., Ebola , malaria, hepatitis and even the common flu, the researchers involved in the development of I.G.T.... (Source: NaturalNews.com)
Source: NaturalNews.com - December 6, 2017 Category: Consumer Health News Source Type: news

Liberia:Prevail Studies Receive High Ratings
[New Dawn] The Partnership for Research on Ebola Virus in Liberia (PREVAIL) has received high marks for its ongoing research program in Liberia. PREVAIL is a joint Liberia-U.S. clinical research program established in 2014 in response to a request by former Liberian Health Minister Dr. Walter Gwinnegale to then U.S. Health and Human Services Secretary Sylvia Burwell to assist Liberia develop vaccines and therapeutics to tackle Ebola. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 16, 2017 Category: African Health Source Type: news

Liberia:Ebola Vaccine Study Gains Momentum Here
[New Dawn] The ongoing PREVAIL Ebola vaccine study has taken roots in Liberia with many communities embracing the idea of helping to find solution to an international public health problem. PREVAIL is the Partnership for Research on Ebola Virus in Liberia, a joint Liberia-US clinical research program established in 2014 in response to a request by former Liberian Health Minister, Dr. Walter Gwenigale to then U.S. Health and Human Services Secretary, Sylvia Burwell to assist Liberia develop vaccines and therapeutics t (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 3, 2017 Category: African Health Source Type: news

Liberia:Test Vaccines Produce Immune Response
[NEWS] Results from PREVAIL I--a large Ebola vaccine study that enrolled more than a thousand Liberians at Redemption Hospital in Monrovia during the first few months of 2015-- have been published in the October 12th issue of The New England Journal of Medicine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 17, 2017 Category: African Health Source Type: news

Medical Terrorists at Large! NMA panel suggests no American has the right to refuse experimental vaccinations and children must be held down by police while injected
(Natural News) Are you ready for your front door to be kicked in by a CDC swat team and your children to be held down at gunpoint while being injected with the latest experimental vaccines for anthrax, zika, ebola, HPV, measles, chicken pox, swine flu, influenza, and whatever else they think up this year? The... (Source: NaturalNews.com)
Source: NaturalNews.com - October 17, 2017 Category: Consumer Health News Source Type: news

Progress on two Ebola vaccines
Two test vaccines for Ebola were safe and induced lasting immune responses in a study with 1,500 adults in Liberia. The findings are an important step in development of a vaccine. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - October 16, 2017 Category: Consumer Health News Source Type: news

Liberia: Test Vaccines Produce Year-Long Immune Response in Most Study Participants
[New Republic] Results from PREVAIL I-a large Ebola vaccine study that enrolled more than a thousand Liberians at Redemption Hospital in Monrovia during the first few months of 2015- have been published in the October 12th issue of The New England Journal of Medicine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 13, 2017 Category: African Health Source Type: news

Liberia:Test Vaccines Produce Year-Long Immune Response in Most Study Participants
[New Republic] Results from PREVAIL I-a large Ebola vaccine study that enrolled more than a thousand Liberians at Redemption Hospital in Monrovia during the first few months of 2015- have been published in the October 12th issue of The New England Journal of Medicine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 13, 2017 Category: African Health Source Type: news

Liberia: Ebola Test Vaccines Produce Year-Long Immune Response in Most Study Participants
[FrontPageAfrica] Monrovia -Results from PREVAIL I--a large Ebola vaccine study that enrolled more than a thousand Liberians at Redemption Hospital in Monrovia during the first few months of 2015-- have been published in the October 12th issue of The New England Journal of Medicine. The results show that the two test vaccines, cAd3-EBOZ and rVSV-ZEBOV, pose no major safety concerns and can produce immune responses within one month after vaccination that last for at least one year. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 12, 2017 Category: African Health Source Type: news

Two Ebola Vaccines Spur Lasting Immune Response
Study confirms the effectiveness of one in particular Source: HealthDay Related MedlinePlus Pages: Ebola, Immunization (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 12, 2017 Category: Consumer Health News Source Type: news

Ebola Vaccines Safe, Yield Immune Responses (CME/CE)
(MedPage Today) -- But clinical efficacy remains unproven (Source: MedPage Today Emergency Medicine)
Source: MedPage Today Emergency Medicine - October 12, 2017 Category: Emergency Medicine Source Type: news

Ebola Vaccines Elicit Immune Responses in Liberian Adults (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM Two investigational vaccines against Ebola virus safely provoked immune responses in a large group of Liberian adults, according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 12, 2017 Category: Primary Care Source Type: news

Experimental Ebola vaccines elicit year-long immune response
NIH reports final data from large clinical trial in West Africa. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - October 11, 2017 Category: American Health Source Type: news

Two Ebola Vaccines Spur Lasting Immune Response
WEDNESDAY, Oct. 11, 2017 -- Two experimental vaccines against the deadly Ebola virus are able to trigger an immune response that lasts for at least a year, a new clinical trial has found. Experts said the results give more support to one of the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 11, 2017 Category: General Medicine Source Type: news

Experimental Ebola vaccines elicit year-long immune response
(NIH/National Institute of Allergy and Infectious Diseases) Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. The findings, published in NEJM, are based on a study of 1,500 adults that began during the West Africa Ebola outbreak. The trial is being conducted by a US-Liberia clinical research collaboration known as PREVAIL. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 11, 2017 Category: Infectious Diseases Source Type: news

The World Health Organization Just Picked Its New Leaders. Most of Them Are Women
The World Health Organization announced its new senior leadership team Tuesday, and more than 60% of the appointees are women. “The team represents 14 countries, including all WHO regions, and is more than 60% women, reflecting my deep-held belief that we need top talent, gender equity and a geographically diverse set of perspectives to fulfill our mission to keep the world safe,” WHO Director-General Dr. Tedros Adhanom Ghebreyesus said in a statement. The five men selected to lead the agency are Dr. Peter Salama, Dr. Bernhard Schwartländer, Dr. Ranieri Guerra, Dr. Ren Minghui, and Stewart Simonson. WHO ...
Source: TIME.com: Top Science and Health Stories - October 4, 2017 Category: Consumer Health News Authors: Casey Quackenbush Tags: Uncategorized onetime United Nations women's empowerment Source Type: news

US Invests $170 Million in Late-Stage Ebola Vaccines, Drugs US Invests $170 Million in Late-Stage Ebola Vaccines, Drugs
The U.S. government is investing more than $170 million to help two new vaccines against the Ebola virus and two Ebola drugs complete the steps needed for approval from the Food and Drug Administration.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

U.S. invests $170 million in late-stage Ebola vaccines, drugs
CHICAGO (Reuters) - The U.S. government is investing more than $170 million to help two new vaccines against the Ebola virus and two Ebola drugs complete the steps needed for approval from the Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - September 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

US invests $170 million in late-stage Ebola vaccines, drugs
CHICAGO (Reuters) - The U.S. government is investing more than $170 million to help two new vaccines against the Ebola virus and two Ebola drugs complete the steps needed for approval from the Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - September 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson Advances Investigational Ebola Prime-boost Vaccine Regimen with New Partnership
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 29, 2017 Category: Pharmaceuticals Source Type: news

HHS accelerates development of first Ebola vaccines and drugs
Hundreds of thousands of Americans could be protected from or treated for Ebola infections through the first purchase of vaccines and therapeutic drugs by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within HHS. (Source: PHPartners.org)
Source: PHPartners.org - September 29, 2017 Category: International Medicine & Public Health Source Type: news

Philanthropists Join Forces to Fund Africa ’s Cash-Strapped Health Sector
Tristate Heart and Vascular Centre in Nigeria. Credit: Tristate Heart and Vascular CentreBy Pavithra Rao, Africa Renewal*NEW YORK, Sep 28 2017 (IPS)In the 2017 World Happiness Report by Gallup, African countries score poorly. Of the 150 countries on the list, the Central African Republic, Tanzania and Burundi rank as the unhappiest countries in the world. Some of the factors driving unhappiness are the poor state of the continent’s health care systems, the persistence of HIV/AIDS, malaria and tuberculosis, and the growth of lifestyle diseases such as hypertension, heart disease and diabetes.Few African countries make...
Source: IPS Inter Press Service - Health - September 28, 2017 Category: International Medicine & Public Health Authors: Pavithra Rao Tags: Development & Aid Featured Global Headlines Health TerraViva United Nations Source Type: news

Jefferson awarded $30M contract to develop Ebola vaccine
The National Institutes of Health has awarded a five-year contract worth up to $30 million to Thomas Jefferson University to prepare and test a vaccine formulation designed to protect against the Ebola, Sudan, Marburg and Lassa fever viruses. The National Institute of Allergy and Infectious Diseases, part of the NIH, made an initial award of $2.6 million to Jefferson for the global project that will be led by principal investigator Matthias Schnell, the chairman of Jefferson's department of microbiology… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 27, 2017 Category: Biotechnology Authors: John George Source Type: news

Ebola: Early immune response provides insight into vaccination
(German Center for Infection Research) The latest outbreaks of emerging pathogens, such as Ebola or Zika, emphasize the importance of the rapid development of vaccines. However, being able to predict the efficacy of new vaccines remains a challenge in vaccine development. DZIF scientists at the Heinrich Pette Institute and the University Medical Centre Hamburg-Eppendorf were successful in their study in assessing early on the longer-term immune response in humans after being vaccinated with the newly developed Ebola vaccine rVSV-ZEBOV. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 7, 2017 Category: Infectious Diseases Source Type: news

Key Technical Documents: Ebola Response
World Health Organization. 05/2017 This one-page document provides quick access to key technical documents and publications on Ebola for responders. Topics include Surveillance, Contact Tracing, and Laboratory; Case Management and Infection Prevention and Control; Vaccines; Therapeutics; and Travel and Points of Entry. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - August 15, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

Einstein Researchers Awarded Three NIH Grants Totaling $12 Million to Fight Virulent Viruses
August 11, 2017—BRONX, NY—The NIH has awarded Einstein researchers three grants totaling more than $12 million to protect against three deadly viruses—Ebola, Marburg and hantavirus. Research collaborations betweenKartik Chandran, Ph.D., professor of microbiology& immunology and the Harold and Muriel Block Faculty Scholar in Virology, andJonathan Lai, Ph.D., associate professor of biochemistry, have led to novel approaches for developing vaccines and treatments. (Source: Einstein News)
Source: Einstein News - August 11, 2017 Category: Universities & Medical Training Source Type: news

Morning Break: Bat Crazy for Ebola; Exercise Pill? Addiction Vaccine
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 11, 2017 Category: Psychiatry Source Type: news

Einstein researchers awarded 3 NIH grants totaling $12 million to fight virulent viruses
(Albert Einstein College of Medicine) The NIH has awarded Einstein researchers three grants totaling more than $12 million to protect against three deadly viruses -- Ebola, Marburg and hantavirus. Research collaborations between Kartik Chandran, Ph.D., professor of microbiology& immunology and the Harold and Muriel Block Faculty Scholar in Virology, and Jonathan Lai, Ph.D. associate professor of biochemistry, have led to novel approaches for developing vaccines and treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 11, 2017 Category: International Medicine & Public Health Source Type: news

Community engagement drives Ebola vaccine trial in Sierra Leone
To ensure the right person takes an Ebola trial vaccine at the right time in Sierra Leone, an EU-industry funded project is employing a combination of low-tech and high-tech community engagement strategies. Today, 450 adults and 96 adolescents are successfully enrolled in a two-stage vaccine trial. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - August 1, 2017 Category: Research Source Type: news

2017 FDA (Food and Drug Administration) Science Forum Webcast
U.S. Food and Drug Administration. 06/19/2017 This Web page provides information, videos, and transcripts from the 2017 Food and Drug Administration Science Forum Webcast on May 31-June 1, 2017. Sessions topics included Development of Mouse Models to Assess Efficacy and Potency of Zika Virus Therapeutics; Development of Total and Neutralizing Anti-Ebola Virus Antibody Assays for Deployment in West Africa to Evaluate Clinical Trials of Medical Countermeasures, including Vaccines and Immunotherapies; and Use of an FDA Real-Time Mobile Communication Platform System during Medical Countermeasure Events: RAPID. (Video or Multim...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - July 19, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

When an emerging disease becomes endemic
Epidemics, such as HIV in the early 1980s and Ebola in 2014, inspire decisive government investment and action, and individual and societal concern, sometimes bordering on panic. By contrast, endemic diseases, such as HIV in 2017 and tuberculosis, struggle to maintain the same attention. For many, the paradox is that endemic disease, in its totality, continues to impose a far higher public health burden than epidemic disease. Overall, the swift political response to epidemics has resulted in success. It has proven possible to eradicate epidemic diseases, often without the availability of vaccines and other biomedical techn...
Source: ScienceNOW - July 13, 2017 Category: Science Authors: Medley, G. F., Vassall, A. Tags: Medicine, Diseases special/review Source Type: news

Three-Zone Biosecurity Offers New Hope to Indonesian Farmers
James McGrane, FAO ECTAD Indonesia Team Leader, at his office in Jakarta. Credit: Kanis Dursin/IPSBy Kanis DursinJAKARTA, Indonesia, Jul 10 2017 (IPS)Poultry farmer Bambang Sutrisno Setiawan had long heard about biosecurity but never gave serious thought to it, even when the highly pathogenic avian influenza H5N1 forced him to cull thousands of his layer chickens in 2003 and 2009.Eighteen years into the business, however, Bambang, who is called Ilung by friends, is now converting his second farm into a three-zone biosecurity poultry with a strong conviction that it is the only way to save his business amid continued threat...
Source: IPS Inter Press Service - Health - July 10, 2017 Category: International Medicine & Public Health Authors: Kanis Dursin Tags: Asia-Pacific Economy & Trade Featured Food & Agriculture Headlines Health Projects avian flu biosafety Food and Agriculture Organization of the United Nations (FAO) Improving the lives of rural populations: better nutrition & agricultu Source Type: news

CEPI (Coalition for Epidemic Preparedness Innovation) Ebola Vaccines Regulatory Science Meeting
Coalition for Epidemic Preparedness Innovations. 05/22/2017 This 10-page report summarizes a regulatory scientific meeting held on March 22, 2017, to address the regulatory science gaps on the Ebola vaccines. It aimed to clarify the current gaps in scientific knowledge and data needed to support licensure of Ebola vaccines via pathways other than traditional approval, i.e., approval in the absence of clinical efficacy data. Participants looked into future regulatory scientific research areas which will be further refined and taken forward in smaller task forces. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medi...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - July 2, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

Guidance Document: Questionnaire on Regulatory Science Issues for the Development of Emerging Infectious Disease (EID) Vaccines
Coalition for Epidemic Preparedness Innovations. 03/29/2017 This four-page document provides guidance on the completion of the CEPI questionnaire on regulatory science issues for development of emerging infectious disease (EID) vaccines. Partners with an interest in securing regulatory approval/licensure of EID vaccines are invited to provide comment on the regulatory scientific issues for the development of EID vaccines. The document provides background information and issues on the prioritized pathogens Ebola, Lassa, Nipah, and Middle East respiratory syndrome (MERS). (PDF) (Source: Disaster Lit: Resource Guide for Disas...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - July 2, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

Community Health Workers: Forgotten No More
June 21, 2017A new global campaign is pushing for salaries, benefits, and formal employment for these crucial health workers.They crisscross the villages, urban settlements, hills, valleys and plains, sometimes on foot, sometimes on bicycles.They wear T-shirts with health messages. They carry bags of tablets, syrups, and health information materials. They mobilize communities to go for vaccinations. They distribute mosquito nets. They supply contraceptives. They accompany women to antenatal clinics and delivery rooms and ensure that they deliver their babies safely.They go by various names such as community health workers ...
Source: IntraHealth International - June 21, 2017 Category: International Medicine & Public Health Authors: mnathe Source Type: news

Ebola vaccine developed in Canada shows promising results
(Canadian Medical Association Journal) A phase 1 randomized controlled trial has found an Ebola virus disease vaccine, developed in Canada, was well-tolerated with no safety concerns, and high antibodies were present in participants six months after immunization. The study, led by Canadian researchers, is published in Canadian Medical Association Journal. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 19, 2017 Category: Infectious Diseases Source Type: news

e-PROTECT Occupational Health and Safety
World Health Organization. 06/2017 This occupational health and safety course covers the basic information needed to protect yourself when deploying to countries with Ebola virus disease. Five modules cover how Ebola is transmitted, what the symptoms are, how it is diagnosed, and what treatments are currently available; infection prevention and control; staff safety, including medical clearance, vaccinations, and other precautions; medical incident management, or what to do if you experience sudden onset of symptoms, if there has been an exposure, or if medical evacuation is needed; and how to carry out debriefing and foll...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - June 16, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

Cholera epidemic in Yemen reaches ‘unprecedented’ scale
Outbreak set to be ‘worst of the century’, warn agencies Related items fromOnMedica Healthcare ‘a tactic of war’ in Iraq and Syria Eastern Mediterranean conflict jeopardising decades of health gains World ’s first malaria vaccine to be piloted World ‘not prepared’ for Zika and Ebola (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 9, 2017 Category: UK Health Source Type: news

Insane Texas Bill That Attacks Abortion From All Sides Just Became Law
On Tuesday, Texas Gov. Greg Abbott signed into law a far-reaching anti-abortion bill that critics have slammed as “cruel” and “unconstitutional.” After a landmark Supreme Court ruling that struck down two Texas abortion restrictions last June, legislators in that state came back with a vengeance, considering some 50 anti-choice measures over the last several months. (Rewire called it an “anti-choice blitz.”) But the newly passed Senate Bill 8 stands out from the rest for the startling breadth with which it attacks abortion rights.  The Center for Reproductive Rights has already pled...
Source: Healthy Living - The Huffington Post - June 7, 2017 Category: Consumer Health News Source Type: news

Antibodies from Ebola survivor could lead to treatments and vaccines
Antibodies from an Ebola survivor protected animals from deadly ebolaviruses and could help inform the development of potential treatments and vaccines. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - June 5, 2017 Category: Consumer Health News Source Type: news